Precision Radiation for Brain Metastases With a Focus on Hypofractionated Stereotactic Radiosurgery

Semin Radiat Oncol. 2023 Apr;33(2):114-128. doi: 10.1016/j.semradonc.2023.01.004.

Abstract

There are multiple published randomized controlled trials supporting single-fraction stereotactic radiosurgery (SF-SRS) for patients presenting with 1 to 4 brain metastases, with the benefit of minimizing radiation-induced neurocognitive sequelae as compared to whole brain radiotherapy . More recently, the dogma of SF-SRS as the only means of delivering an SRS treatment has been challenged by hypofractionated SRS (HF-SRS). The ability to deliver 25-35 Gy in 3-5 HF-SRS fractions is a direct consequence of the evolution of radiation technologies to allow image guidance, specialized treatment planning, robotic delivery and/or patient positioning corrections in all 6 degrees-of-freedom, and frameless head immobilization. The intent is to mitigate the potentially devastating complication of radiation necrosis and improve rates of local control for larger metastases. This narrative review provides an overview of outcomes specific to HF-SRS in addition to the more recent developments of staged SRS, preoperative SRS, and hippocampal avoidance-whole brain radiotherapy with simultaneous integrated boost.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / pathology
  • Brain Neoplasms* / radiotherapy
  • Brain Neoplasms* / surgery
  • Disease Progression
  • Humans
  • Patient Positioning
  • Radiosurgery* / adverse effects
  • Radiosurgery* / methods